Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 20/20 | 0.78 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606486 | 0.93 | HRH4 (0.81) | HRH4HRH3KCNH2 | |
| SCHEMBL1775251 | 0.86 | HRH4 (0.71) | HRH4HRH3KCNH2 | |
| SCHEMBL1775050 | 0.84 | HRH4 (0.74) | HRH4HRH3KCNH2 | |
| Adriforant SCHEMBL18636602 | 0.84 | HRH4 (1.00) | HRH4HRH3KCNH2 | |
| Adriforant SCHEMBL12604990 | 0.84 | HRH4 (1.00) | HRH4HRH3KCNH2 | |
| SCHEMBL605509 | 0.83 | HRH4 (0.76) | HRH4HRH3KCNH2 | |
| SCHEMBL17908156 | 0.83 | HRH4 (1.00) | HRH4HRH3KCNH2 | |
| Adriforant SCHEMBL20483890 | 0.83 | HRH4 (0.98) | HRH4HRH3KCNH2 | |
| SCHEMBL603668 | 0.81 | HRH4 (1.00) | HRH4HRH3KCNH2 | |
| SCHEMBL1775524 | 0.81 | HRH4 (0.67) | HRH4HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135787-A1 | PYRIMIDINE COMPOSITIONS, ULTRA-PURE COMPOSITIONS AND SALTS THEREOF, METHODS OF MAKING THE SAME, AND METHODS OF USING THE SAME FOR TREATING HISTAMINE H4 RECEPTOR (H4) MEDIATED DISEASES AND CONDITIONS | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| US-20170158671-A1 | PYRIMIDINE COMPOSITIONS, ULTRA PURE COMPOSITIONS AND SALTS THEREOF, METHODS OF MAKING THE SAME, AND METHODS OF USING THE SAME FOR TREATING HISTAMINE H4 RECEPTOR (H4) MEDIATED DISEASES AND CONDITIONS | Ziarco Pharma Ltd. (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158671-A1 | PYRIMIDINE COMPOSITIONS, ULTRA PURE COMPOSITIONS AND SALTS THEREOF, METHODS OF MAKING THE SAME, AND METHODS OF USING THE SAME FOR TREATING HISTAMINE H4 RECEPTOR (H4) MEDIATED DISEASES AND CONDITIONS | Ziarco Pharma Ltd. (GB) | 2017-06-08 | — | — | US | disclosed |
| WO-2017072131-A1 | PYRIMIDINE COMPOSITIONS, ULTRA-PURE COMPOSITIONS AND SALTS THEREOF, METHODS OF MAKING THE SAME, AND METHODS OF USING THE SAME FOR TREATING HISTAMINE H4 RECEPTOR (H4) MEDIATED DISEASES AND CONDITIONS | ZIARCO PHARMA LIMITED (GB) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158671-A1 | PYRIMIDINE COMPOSITIONS, ULTRA PURE COMPOSITIONS AND SALTS THEREOF, METHODS OF MAKING THE SAME, AND METHODS OF USING THE SAME FOR TREATING HISTAMINE H4 RECEPTOR (H4) MEDIATED DISEASES AND CONDITIONS | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885KCNH2 1281/4885 |
| US-20190135787-A1 | PYRIMIDINE COMPOSITIONS, ULTRA-PURE COMPOSITIONS AND SALTS THEREOF, METHODS OF MAKING THE SAME, AND METHODS OF USING THE SAME FOR TREATING HISTAMINE H4 RECEPTOR (H4) MEDIATED DISEASES AND CONDITIONS | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885KCNH2 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.